AU2016375566A1 - Polymorphic crystalline forms of obeticholic acid - Google Patents
Polymorphic crystalline forms of obeticholic acid Download PDFInfo
- Publication number
- AU2016375566A1 AU2016375566A1 AU2016375566A AU2016375566A AU2016375566A1 AU 2016375566 A1 AU2016375566 A1 AU 2016375566A1 AU 2016375566 A AU2016375566 A AU 2016375566A AU 2016375566 A AU2016375566 A AU 2016375566A AU 2016375566 A1 AU2016375566 A1 AU 2016375566A1
- Authority
- AU
- Australia
- Prior art keywords
- pct
- obeticholic acid
- acid
- crystalline
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C[C@](CCC(O)=O)[C@@](CC1)[C@@](C)(CCC2[C@@](C)(CC[C@](C3)O)[C@@]3[C@]3*)C1C2[C@@]3O Chemical compound C[C@](CCC(O)=O)[C@@](CC1)[C@@](C)(CCC2[C@@](C)(CC[C@](C3)O)[C@@]3[C@]3*)C1C2[C@@]3O 0.000 description 3
- DXOCDBGWDZAYRQ-MEFUFCBTSA-N CC(CCC(O)=O)[C@@H](CC1)[C@@](C)(CC[C@@H]2[C@@](C)(CC[C@H](C3)O)[C@@H]3C3)[C@@H]1[C@@H]2C3=O Chemical compound CC(CCC(O)=O)[C@@H](CC1)[C@@](C)(CC[C@@H]2[C@@](C)(CC[C@H](C3)O)[C@@H]3C3)[C@@H]1[C@@H]2C3=O DXOCDBGWDZAYRQ-MEFUFCBTSA-N 0.000 description 1
- GRQROVWZGGDYSW-DHRNRZGUSA-N CC(CCC(OC)=O)[C@@H](CC1)[C@@](C)(CC[C@@H]2[C@@](C)(CC[C@H](C3)O)[C@@H]3C3)[C@@H]1[C@@H]2C3O Chemical compound CC(CCC(OC)=O)[C@@H](CC1)[C@@](C)(CC[C@@H]2[C@@](C)(CC[C@H](C3)O)[C@@H]3C3)[C@@H]1[C@@H]2C3O GRQROVWZGGDYSW-DHRNRZGUSA-N 0.000 description 1
- RDCBMNFSJFALPG-IQVFBFPCSA-N C[C@H](CCC(O)=O)C(CC1)[C@@](C)(CCC2[C@@](C)(CC[C@H](C3)O)C3/C3=C\C)C1C2C3=O Chemical compound C[C@H](CCC(O)=O)C(CC1)[C@@](C)(CCC2[C@@](C)(CC[C@H](C3)O)C3/C3=C\C)C1C2C3=O RDCBMNFSJFALPG-IQVFBFPCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/979,005 | 2015-12-22 | ||
| US14/979,005 US9982008B2 (en) | 2012-06-19 | 2015-12-22 | Preparation and uses of obeticholic acid |
| PCT/US2016/012651 WO2017111979A1 (en) | 2015-12-22 | 2016-01-08 | Polymorphic crystalline forms of obeticholic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016375566A1 true AU2016375566A1 (en) | 2018-07-05 |
Family
ID=55650649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016375566A Abandoned AU2016375566A1 (en) | 2015-12-22 | 2016-01-08 | Polymorphic crystalline forms of obeticholic acid |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3394081A1 (ja) |
| JP (1) | JP2018538331A (ja) |
| KR (1) | KR20180095070A (ja) |
| CN (1) | CN108495858A (ja) |
| AU (1) | AU2016375566A1 (ja) |
| BR (1) | BR112018012590A2 (ja) |
| CA (1) | CA3009149A1 (ja) |
| CL (1) | CL2018001720A1 (ja) |
| CO (1) | CO2018006701A2 (ja) |
| EA (1) | EA201891491A1 (ja) |
| IL (1) | IL259998A (ja) |
| MX (1) | MX2018007776A (ja) |
| PH (1) | PH12018501318A1 (ja) |
| SG (1) | SG11201805235XA (ja) |
| WO (1) | WO2017111979A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105801653B (zh) * | 2014-12-30 | 2018-04-17 | 苏州晶云药物科技有限公司 | 奥贝胆酸的晶型a及其制备方法 |
| WO2018211413A1 (en) * | 2017-05-15 | 2018-11-22 | Dr. Reddy’S Laboratories Limited | Solid forms of obeticholic acid and process for preparation |
| CN109280071A (zh) * | 2017-07-19 | 2019-01-29 | 东莞东阳光药物研发有限公司 | 奥贝胆酸的晶型及其制备方法 |
| CN107383139A (zh) * | 2017-08-09 | 2017-11-24 | 杭州和泽医药科技有限公司 | 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法 |
| CZ31099U1 (cs) * | 2017-09-05 | 2017-10-17 | Zentiva, K.S. | Krystalické formy (3a,5B,6a,7a)-6-ethyl-3,7- dihydroxycholan-24-ové kyseliny |
| CN109485687A (zh) * | 2017-09-12 | 2019-03-19 | 成都弘达药业有限公司 | 奥贝胆酸的晶型j及其制备方法 |
| WO2019106043A1 (en) | 2017-11-29 | 2019-06-06 | Hexal Ag | Pharmaceutical composition comprising obeticholic acid |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN113264972B (zh) * | 2020-02-14 | 2024-07-12 | 四川科伦药物研究院有限公司 | 一种制备奥贝胆酸的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| KR101881245B1 (ko) * | 2012-06-19 | 2018-07-23 | 인터셉트 파마슈티컬즈, 인크. | 오베티콜산의 제조법, 용도 및 고체 형태 |
| CN106459136B (zh) * | 2014-09-28 | 2018-06-26 | 江苏盛迪医药有限公司 | 一种奥贝胆酸的制备方法 |
| JP6700274B2 (ja) * | 2014-11-19 | 2020-05-27 | エヌゼットピー ユーケー リミテッド | ステロイドｆｘｒモジュレーター製造のための中間体としての６−アルキル−７−ヒドロキシ−４−エン−３−オンステロイド |
| TWI686401B (zh) * | 2014-11-19 | 2020-03-01 | 英商Ｎｚｐ英國有限公司 | 化合物（三） |
| EA033603B1 (ru) * | 2014-11-19 | 2019-11-08 | Nzp Uk Ltd | 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| CA2968301C (en) * | 2014-11-19 | 2023-05-16 | NZP UK Limited | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators |
-
2016
- 2016-01-08 BR BR112018012590A patent/BR112018012590A2/pt not_active Application Discontinuation
- 2016-01-08 EP EP16714049.0A patent/EP3394081A1/en not_active Withdrawn
- 2016-01-08 CN CN201680079793.8A patent/CN108495858A/zh active Pending
- 2016-01-08 JP JP2018532396A patent/JP2018538331A/ja active Pending
- 2016-01-08 KR KR1020187020850A patent/KR20180095070A/ko unknown
- 2016-01-08 MX MX2018007776A patent/MX2018007776A/es unknown
- 2016-01-08 AU AU2016375566A patent/AU2016375566A1/en not_active Abandoned
- 2016-01-08 WO PCT/US2016/012651 patent/WO2017111979A1/en active Application Filing
- 2016-01-08 CA CA3009149A patent/CA3009149A1/en not_active Abandoned
- 2016-01-08 EA EA201891491A patent/EA201891491A1/ru unknown
- 2016-01-08 SG SG11201805235XA patent/SG11201805235XA/en unknown
-
2018
- 2018-06-13 IL IL259998A patent/IL259998A/en unknown
- 2018-06-20 PH PH12018501318A patent/PH12018501318A1/en unknown
- 2018-06-22 CL CL2018001720A patent/CL2018001720A1/es unknown
- 2018-06-27 CO CONC2018/0006701A patent/CO2018006701A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3394081A1 (en) | 2018-10-31 |
| PH12018501318A1 (en) | 2019-02-18 |
| CO2018006701A2 (es) | 2018-07-10 |
| MX2018007776A (es) | 2018-08-09 |
| BR112018012590A2 (pt) | 2018-12-04 |
| KR20180095070A (ko) | 2018-08-24 |
| EA201891491A1 (ru) | 2018-11-30 |
| SG11201805235XA (en) | 2018-07-30 |
| CA3009149A1 (en) | 2017-06-29 |
| CL2018001720A1 (es) | 2018-08-10 |
| CN108495858A (zh) | 2018-09-04 |
| IL259998A (en) | 2018-07-31 |
| JP2018538331A (ja) | 2018-12-27 |
| WO2017111979A1 (en) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018241172B2 (en) | Preparation, uses and solid forms of obeticholic acid | |
| US9982008B2 (en) | Preparation and uses of obeticholic acid | |
| AU2016375566A1 (en) | Polymorphic crystalline forms of obeticholic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period | ||
| NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 07 MAY 2020 |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |